tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
4D Molecular Therapeutics, Inc. (FDMT)
:FDMT
US Market
FDMT
4D Molecular Therapeutics
Overview
Analyst Forecasts
Financials
Dividends
Technical Analysis
Options
Chart
Earnings
Ownership
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports

4D Molecular Therapeutics (FDMT) Stock News & Sentiment

Compare
339 Followers
Optimistic Buy Rating for 4D-150 Driven by PRISM Study’s Promising Results in Treating Wet Age-Related Macular Degeneration
Premium
Ratings
Optimistic Buy Rating for 4D-150 Driven by PRISM Study’s Promising Results in Treating Wet Age-Related Macular Degeneration
12d ago
FDMT
Cautious ‘Hold’ Rating on 4D Molecular Therapeutics Amidst Competitive Market and Investor Concerns
Premium
Ratings
Cautious ‘Hold’ Rating on 4D Molecular Therapeutics Amidst Competitive Market and Investor Concerns
12d ago
FDMT
4D Molecular Therapeutics: Strong Buy Rating on Promising 4D-150 Gene Therapy Data and Strategic Phase 3 Trials
Premium
Ratings
4D Molecular Therapeutics: Strong Buy Rating on Promising 4D-150 Gene Therapy Data and Strategic Phase 3 Trials
12d ago
FDMT
Promising Prospects for 4D Molecular Therapeutics: Anticipated Growth in wAMD Treatment and Market Valuation
Premium
Ratings
Promising Prospects for 4D Molecular Therapeutics: Anticipated Growth in wAMD Treatment and Market Valuation
16d ago
FDMT
4D Molecular Therapeutics’ Positive Q3 and Strategic Advances
Premium
Company Announcements
4D Molecular Therapeutics’ Positive Q3 and Strategic Advances
3M ago
FDMT
4D Molecular Therapeutics to Present PRISM Trial Interim Data
Premium
Company Announcements
4D Molecular Therapeutics to Present PRISM Trial Interim Data
7M ago
8K
FDMT
4D Molecular Therapeutics Secures Major Financial Deal
Premium
Company Announcements
4D Molecular Therapeutics Secures Major Financial Deal
1y ago
8K
FDMT
More FDMT News >

FDMT News on the Web

4DMT to Participate in Upcoming Investor Conferences
Yahoo Finance
Neutral
Chardan Capital Keeps Their Buy Rating on 4D Molecular Therapeutics (FDMT)
TipRanks News
Bullish
4D Molecular's wAMD drug is best-in-class, says RBC, sees 'ideal' entry point
The Fly
Neutral
4D Molecular Therapeutics Reports Positive Interim Data From Phase 2b Trial For Wet AMD
rttnews
Neutral
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
Yahoo Finance
Neutral
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
Yahoo Finance
Neutral
Top US Penny Stocks To Watch In January 2025
Yahoo Finance
Neutral
H.C. Wainwright Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
FDMT
Sector Average
Media Buzz
This Week1 articles
Weekly Average1.5 articles
News Sentiment
This Week59%
Sector Average57%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is FDMT’s Media Buzz Sentiment?
1 articles about FDMT were published this week. In an average week, 1.5 articles are published.
    What is FDMT’s weekly average amount of articles?
    In an average week, 1.5 articles about FDMT are published.
      What is FDMT’s News Sentiment?
      59% of articles about FDMT were positive this week, compared to its sector average of 57%.
        Healthcare Stocks that are Trending in the News
        SHGSingular Health Group Ltd
        RCUSArcus Biosciences
        HCMHUTCHMED
        PENPenumbra
        AMNAMN Healthcare Services
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing